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Abstract
Background: Although several anti-angiogenic therapies have been approved in the treatment of cancer, the survival 
benefits of such therapies are relatively modest. Discovering new molecules and/or better understating signaling 
pathways of angiogenesis is therefore essential for therapeutic improvements. The objective of the present study was 
to determine the involvement of nerve growth factor (NGF) in breast cancer angiogenesis and the underlying 
molecular mechanisms.
Results: We showed that both recombinant NGF and NGF produced by breast cancer cells stimulated angiogenesis in 
Matrigel plugs in immunodeficient mice. NGF strongly increased invasion, cord formation and the monolayer 
permeability of endothelial cells. Moreover, NGF-stimulated invasion was under the control of its tyrosine kinase 
receptor (TrkA) and downstream signaling pathways such as PI3K and ERK, leading to the activation of matrix 
metalloprotease 2 and nitric oxide synthase. Interestingly, NGF increased the secretion of VEGF in both endothelial and 
breast cancer cells. Inhibition of VEGF, with a neutralizing antibody, reduced about half of NGF-induced endothelial cell 
invasion and angiogenesis in vivo.
Conclusions: Our findings provided direct evidence that NGF could be an important stimulator for breast cancer 
angiogenesis. Thus, NGF, as well as the activated signaling pathways, should be regarded as potential new targets for 
anti-angiogenic therapy against breast cancer.
Background
It is well established that tumor growth beyond the size of
1-2 mm is dependent upon angiogenesis [1]. This process
is regulated by numerous proangiogenic factors which
are secreted by tumor or surrounding stromal cells.
Among these proangiogenic factors, vascular endothelial
growth factor (VEGF) plays a pivotal role in tumor angio-
genesis. VEGF promotes angiogenesis via its ability to
stimulate permeability, growth, migration and invasion of
endothelial cells, and to mobilize endothelial precursor
cells from bone marrow [2-4]. Inhibition of VEGF
reduces angiogenesis and tumor growth in vivo [5]. Con-
versely, VEGF overexpression is associated with
increased microvessel density, tumor metastasis, and
poor prognosis [6-8]. Among several VEGF isoforms,
VEGF-A is the most predominant angiogenic factor, as its
level is strongly associated with tumor progression and
poor clinical outcome in many types of cancers including
breast cancer [9-11].
NGF has been studied most extensively for its role in
regulating growth, development, survival and regenera-
tion of the nervous system. NGF exerts its effects through
two membrane receptors: the tyrosine kinase receptor
TrkA and the neurotrophin receptor p75NTR, a common
receptor for all neurotrophins and pro-neurotrophins.
NGF binding to TrkA induces TrkA receptor dimerisa-
tion and autophosphorylation of cytoplasmic tyrosines,
leading to the activation of various signaling pathways,
including Ras/MAPK, PLCγ, and PI3K/Akt [12,13]. NGF
has also been reported to promote angiogenesis and/or
induces the expression of proangiogenic molecules in
several tissues, such as muscle and cornea [14-16]. On the
other hand, NGF has been increasingly described to reg-
ulate tumor growth and progression of non-neuronal
cancers including medullar thyroid carcinoma [17], lung
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[18], pancreatic [19], prostatic [20] and breast carcinomas
[21-23]. In breast cancers, we have previously shown that
NGF and its tyrosine kinase receptor TrkA are overex-
pressed compared to normal breast tissues [24,25]. Inhi-
bition of NGF with neutralizing antibodies, or small
interfering RNA, strongly reduces angiogenesis and
tumor development in immunodeficient mice [24]. Con-
versely, TrkA overexpression in breast cancer cells leads
to a constitutive activation of its tyrosine kinase, resulting
in increased tumorigenicity as well as enhanced angio-
genesis [25]. Similar link between NGF and angiogenesis
has also been suggested in ovarian carcinomas [26].
The objective of the present study was to better deter-
mine the possible involvement of NGF in breast cancer
angiogenesis, as well as the underlying molecular mecha-
nisms. We showed that NGF secreted by breast cancer
cells could stimulate tumor angiogenesis in vivo. NGF
increased growth, migration, invasion, tubular formation
and permeability of endothelial cells. We also demon-
strated the involvement of multiple pathways such as
PI3K-Akt, ERK, MMP2, and NO synthase as well as the
role of VEGF in the angiogenic effect of NGF.
Materials and Methods
Reagents
Human recombinant NGF and VEGF, neutralizing anti-
bodies against NGF, VEGF and the corresponding isotype
control antibodies were purchased from R&D Systems.
Growth factor-reduced Matrigel was from BD Biosci-
ences. Cleavage resistant proNGF was from Alomone
(Israël).
Cell Culture
Human umbilical vein endothelial cells (HUVEC) from
Lonza were a pool derived from 3 donors. Cells were
maintained at 37°C with humidified 95% air/5% CO2 in
endothelial growth medium (EGM) containing 2% fetal
bovine serum (FBS) and other compounds of the EGM
singlequots provided with the medium (Lonza). For dif-
ferent experiments, HUVEC were cultured in starved
medium composed of endothelial basal medium (EBM)
containing 0.5% FBS and GA-1000 (provided in the EGM
singlequots). MDA-MB-231 human breast cancer cells
from American Type Culture Collection were maintained
in Minimal Essential Medium (MEM) supplemented with
20 mM HEPES, 2 g/l sodium bicarbonate, 2 mM L-glu-
tamine, 1% of non-essential amino acids, 10% fetal calf
serum (FCS).
In vivo Angiogenesis
Six-week-old female severe combined immunodeficient
(SCID) mice were from Institut Pasteur de Lille, France.
Mice were maintained in accordance with the Institu-
tional Animal Care and Use Committee procedures and
guidelines. Angiogenesis was analyzed by Matrigel plug
assay, as described below.
Matrigel plug assay
To determine the influence of endogenously produced
NGF in breast cancer angiogenesis, cold Matrigel was
mixed with MDA-MB-231 breast cancer cells in the pres-
ence of isotype control, or anti-NGF neutralizing anti-
bodies (75 μg/ml). To determine the influence of
recombinant NGF in angiogenesis, cold Matrigel was
mixed with PBS (as control), 3.75 μg/ml NGF, 7.5 μg/ml
proNGF, or 0.375 μg/ml VEGF. In some experiments,
cold Matrigel was also mixed with 3.75 μg/ml NGF and
isotype control or anti-VEGF (37.5 μg/ml) neutralizing
antibodies. A total of 500 μl of the mixed Matrigel was
subcutaneously injected into SCID mice in the middle
lateral dorsal region. Seven days later, the animals were
sacrificed and the Matrigel plugs were harvested. Pictures
of Matrigel plug were taken with a Sony DSC-W5 numer-
ical camera.
Hemoglobin quantification
Hemoglobin quantification was performed as previously
described [27]. Briefly, the Matrigel plugs were homoge-
nized in 500 μl water on ice and cleared by centrifugation
at 200 g for 6 min at 4°C. The supernatant was collected
and used in triplicate to measure hemoglobin content
with Drabkin's reagent (Sigma-Aldrich) according to
manufacturer instruction. The absorbance was measured
at 540 nm.
Microvessel density analysis
Matrigel plugs were fixed in 4% paraformaldehyde,
embedded in paraffin and sections cut at 3-4 μm inter-
vals. Detection of the specific marker of endothelial cell
CD31 by immunohistochemistry was performed with the
Renaissance TSA Biotin System kit (PerkinElmer). The
antibody used for immunohistochemistry against CD31
was from Novus Biologicals and the corresponding bioti-
nylated anti rat secondary antibody was from BD
Pharmingen. The reaction was developed with DAB sub-
strate (Sigma-Aldrich) and sections were counterstained
with Mayer's hematoxylin (Sigma-Aldrich). The microve-
ssel density was quantified in 10 vascular hot-spot fields,
by determining the area covered by CD31-positive stain-
ing, using image analysis, as previously described [28].
Endothelial cell behaviour assays in culture
Endothelial cell growth Assay
HUVEC (105 cells/well) were seeded in six well plates in 2
ml EBM/0.5% FBS and cultured for 24 h. Cells were then
treated with 100 ng/ml NGF or 10 ng/ml VEGF for 48 h.
They were harvested by trypsinization and counted using
a hemocytometer (Coulter Z2, Beckman-Coulter).
Endothelial cell migration and invasion
BD Falcon inserts with a polyethylene terephthalate
(PET) membrane/8 μm pores (BD Biosciences) were usedRomon et al. Molecular Cancer 2010, 9:157
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for migration and invasion assays. The inserts were pre-
coated with diluted Matrigel (1:100 for migration and
1:10 for invasion). HUVEC (5.104  cells/insert) were
seeded into the inserts in EBM/0.5% FBS. Six hours (for
migration) or 24 h (for invasion) later, the inserts were
washed with PBS, and cells on the top surface of the
insert were removed by wiping with a cotton swab. Cells
that migrated to the bottom surface of the insert were
fixed with methanol and stained by Hoechst 33258 and
then subjected to fluorescent microscopic inspection.
Cells were counted in 10 random fields at 200× magnifi-
cation under Nikon Eclipse Ti-U fluorescent microscope.
Endothelial cell cord formation assay
Matrigel (250 μl) was added into wells of 24-well plates,
and polymerized for 30 min at 37°C. HUVEC were then
seeded on the surface of polymerized Matrigel (5.104
cells/well) and cultured in the presence of NGF (100 ng/
ml) or VEGF (10 ng/ml) for 18 h. Tubular networks in
each well were photographed using Nikon Eclipse Ti-U
inverted microscope before measurement of tubular
lengths using NIS element Basic Research (Nikon).
Endothelial cell monolayer permeability assay
HUVEC (2.105  cells/well) were seeded on BD Falcon
inserts with a PET membrane/0.4 μm pores (BD Biosci-
ences) in EGM. When cells reached confluence, they
were treated with NGF (100 ng/ml) or VEGF (10 ng/ml)
in EBM/0.5% FBS for 6 h. The medium was then replaced
with EBM/0.5% FBS containing FITC-labeled dextran (70
kDa, 250 μg/ml, Sigma-aldrich). To determine the fluo-
rescence intensity of FITC-Labeled dextran that passed
through the insert, 100 μl medium was collected from
each well every 15 min during 1 h, and the fluorescence
was measured using a fluorescence multi-well plate
reader FLx800 (Bio-Tek Instrument) at 483 nm as excita-
tion, and 517 nm as emission, wavelengths.
Pharmacological inhibition
Inhibition was performed with 10 nM K252a (tyrosine
inhibitor of TrkA receptor), 10 μM LY294002 (inhibitor
of PI3K), 10 μM PD98059 (inhibitor of MEK 1/2), 10 μM
GM6001 (broad spectrum inhibitor of matrix metalopro-
tease), 5 μM MMP 2 inhibitor I (inhibitor of Matrix Met-
aloprotease 2) or 0.1 mM L-NAME (inhibitor of nitric
oxide synthase). Control cells were treated with DMSO.
The concentrations used were based upon the absence of
toxicity in HUVEC, as determined by bleu Trypan assay
in EBM/0.5% FBS for 24 h. All the inhibitors were from
Calbiochem, except L-NAME (Sigma-Aldrich).
Western blot
Cells were lysed in RIP A buffer (50 mM T ris HCl, 150
mM NaCl, 1 mM EDTA, 1% NP40, 0.25% sodium desoxy-
cholate, 1:100 protease inhibitor cocktail and 1 mM
sodium orthovanadate, all chemicals from Sigma-
Aldrich) and proteins were separated by SDS-PAGE and
then transferred to nitrocellulose membrane (Protran
0.45 μm, Whatman) or polyvinylidene fluoride mem-
brane (Immobulon-P 0.45 μm, Millipore) by liquid trans-
fer.
Blots were blocked in 5% BSA, or 3% non fat skimmed
milk, in Tris-Buffer Saline Tween-20 (TBST, 20 mM Tris
Base, 150 mM NaCl, 0.1% Tween 20) for 1 h at room tem-
perature, and then followed by incubation overnight at
4°C with the primary antibodies against phospho TrkA
(Tyr490), TrkA (Clone 763), phospho NOS (ser1177),
NOS, phospho ERK (Thr202/Tyr204), ERK, phospho Akt
(Ser473) and Akt. All the antibodies were from Cell Sig-
naling and used at 1:1 000 dilution, except anti TrkA
(1:500 dilution, Santa Cruz Biotechnology). After several
washes with TBST, membranes were incubated with the
horseradish peroxidase-linked anti-rabbit or anti-mouse
secondary antibodies (1:10 000 dilution, Jackson Immu-
noresearch) in 5% BSA in TBST for 1 h at room tempera-
ture. Immunoblots were visualized by enhanced
chemiluminescence (Supersignal West Pico, Perbio)
using chemiluminescence film (Amersham) or Fuji LAS-
4000 Mini, according to manufacturers' protocol.
Nitric oxide (NO) quantification with DAF-2DA
NO quantification was performed as previously
described [29]. Briefly, HUVEC were seeded in 96 well-
plates (3.104 cells/well) and cultured for 24 h. Cells were
then pretreated in EBM/0.5% FBS, with or without the
nitric oxide synthase (NOS) inhibitor L-NAME, for 30
min at 37°C. Cells were then loaded with Diaminofluores-
cein -2 Diacetate (DAF-2DA )(5 μM final concentration,
Sigma-Aldrich) for 20 min. After 2 washes, HUVEC were
treated with NGF (100 ng/ml) or VEGF (10 ng/ml) in
presence or absence of L-NAME (Sigma) for 2 h. The flu-
orescence intensity was measured with a multiwell plate
reader FLx80 (Bio-tek instrument) using 490 nm as exci-
tation and 520 nm as emission wavelengths. For the fluo-
r e s c e n c e  i m a g e r y ,  c e l l s  w e r e  s e e d e d  o n  8  w e l l - L a b t e k
chamber slides (5.104 cells/well). Following experiment,
cells were fixed and mounted and pictures were taken
with Nikon Eclipse Ti-U fluorescent microscope.
Gelatin zymography analysis
The presence and activity of MMP-2 in conditioned
medium from HUVEC were analyzed by zymography in
10% SDS-polyacrylamide gel/0.1% gelatin (Sigma-
aldrich), according to manufacturer's protocol.
ELISA detection of secreted VEGF
HUVEC or MDA-MB-231 cells were seeded on 60 mm
d i s h e s  i n  c o m p l e t e  m e d i a.  T h e  f o l l o w i n g  d a y ,  H UV E C
were cultured in 2 ml EBM/0.5% FBS and MDA-MB-231
in 2 ml serum-free MEM in the presence of NGF (100 ng/Romon et al. Molecular Cancer 2010, 9:157
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ml) for 6 h or 24 h. The conditioned media were collected
and concentrated with Amicon Ultra-4 10 K (Millipore)
according to the manufacturer's instruction. Protein con-
tent was then measured with BCA method before ELISA
quantification of VEGF according to manufacturer's
instructions (Human VEGF Duoset kit from R&D Sys-
tems).
Statistical analysis
The data are presented as the mean ± standard deviation
(S.D.) of at least three separate experiments in triplicate.
Comparisons between two groups were analyzed using
the two-tailed Student's t-test or two-way non-paramet-
ric ANOVA test, and significance was established at a p
value <0.05.
Results
NGF contributes to stimulate breast cancer angiogenesis in 
vivo
To determine the potential effect of NGF in breast cancer
angiogenesis, we first performed Matrigel plug assay in
SCID mice (Fig. 1A and 1B). Seven days after the experi-
ment, MDA-MB-231 breast cancer cells strongly induced
capillary vessel formation in Matrigel plugs, as revealed
by hemoglobin content (Fig. 1A) and microvessel density
in Matrigel plugs (Fig. 1B). The presence of a neutralizing
antibody anti-NGF in the Matrigel plugs decreased about
two third the quantity of hemoglobin and microvessel
density, suggesting that NGF is strongly involved in
breast cancer angiogenesis (Fig. 1A and 1B). Moreover,
recombinant NGF induced angiogenesis as efficiently as
recombinant VEGF, while proNGF did not induce angio-
genesis compared to control (Fig. 1C)
NGF exerts pleiotropic effects on human umbilical 
endothelial cells (HUVEC)
The strong involvement of NGF in breast cancer angio-
genesis prompted us to determine the effects of NGF on
endothelial cells in terms of proliferation, migration,
invasion, cord formation and permeability, as all these
processes are known to be involved in tumor angiogene-
sis. We used the well known prototypic angiogenic factor
VEGF as positive control. For this, different concentra-
tions of NGF and VEGF were tested; the maximal effects
were obtained with 100 ng/ml NGF or 10 ng/ml VEGF,
higher concentrations exerted similar effects (data not
shown). To simplify the presentation, we show only
results obtained with 100 ng/ml NGF or 10 ng/ml VEGF.
As shown in Fig. 2A and 2B, NGF stimulated proliferation
and migration of HUVEC, but not as strongly as VEGF. It
is to be noted that upon 24 h of treatment with NGF, no
modification of cell proliferation was observed (data not
shown). In contrast, NGF stimulated HUVEC invasion
(Fig. 2C) and cord formation as strongly as VEGF (Fig.
2D). Similar to VEGF, NGF increased also the permeabil-
ity of HUVEC monolayer (Fig. 2E).
NGF-stimulated invasion of HUVEC involves the activation 
of TrkA and multiple downstream pathways
As invasion of endothelial cells is an important step in
angiogenesis, and as NGF stimulated HUVEC invasion,
we decided to determine different signaling pathways
involved in NGF-stimulated invasion. As shown in Fig.
3A, upon NGF treatment, TrkA phosphorylation was
increased within 10 minutes. Concomitantly, the levels of
phospho Akt (pAkt) and phospho ERK (pERK) were
increased within 10 minutes and remained high even
after 2 h of treatment with NGF. Furthermore, pharmaco-
logical inhibition of TrkA (K252a), PI3K (LY294002) and
MEK 1/2 (PD98059) (Fig. 3B) totally abolished NGF-
stimulated invasion (Fig. 3C). This suggested that NGF-
stimulated invasion of HUVEC was mediated by its
tyrosine kinase TrkA and the downstream pathways
including PI3K and ERK.
Matrix metalloproteases (MMPs) are essential in
matrix degradation during cell invasion. We therefore
used the MMP broad spectrum inhibitor (GM6001) and
the specific inhibitor of MMP2 (MMP2 inhibitor I) to
determine the involvement of MMPs in NGF-stimulated
invasion of HUVEC. As shown in Fig. 4A, the two inhibi-
tors totally abolished NGF-stimulated invasion. Concom-
itantly, gelatin zymography analysis (Fig. 4B and 4C)
showed that NGF did increase the levels of MMP2 active
form in conditioned medium from HUVEC; treatment of
HUVEC with GM6001 or MMP2 inhibitor I totally abol-
ished NGF-induced activation of MMP2 (Fig. 4B). In
addition, inhibitors of TrkA (K252a), PI3K (LY294002)
and MEK 1/2 (PD98059) abolished the NGF-induced
active form of MMP2 (Fig. 4C). Together, these findings
suggested that NGF-stimulated invasion of HUVEC
involved MMPs, particularly MMP2, which was under
the control of PI3K and ERK pathways.
PI3K/Akt pathway has been reported to phosphorylate
NO synthase (NOS), thus increasing NO production
which is responsible for VEGF-induced endothelial cell
migration [30,31]. Here, we showed that NGF also
increased the levels of both phospho NOS (pNOS) (Fig.
5A) and NO in HUVEC (Fig. 5B and 5C). Moreover, NOS
inhibition with L-NAME drastically decreased NGF-
induced NO production (Fig. 5B and 5C) as well as NGF-
stimulated invasion of HUVEC (Fig. 5D). These data sug-
gested that NGF-stimulated invasion of HUVEC involved
the activation of NOS.
NGF-stimulated breast cancer angiogenesis partially 
involves VEGF
It has been described that NGF can stimulate the expres-
sion of VEGF in several types of cells including endothe-Romon et al. Molecular Cancer 2010, 9:157
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Figure 1 Angiogenesis assay using Matrigel plugs in SCID mice. Matrigel containing different reagents was subcutaneously injected into SCID 
mice as described in materials and methods. (A, B) Matrigel was mixed with MDA-MB-231 breast cancer cells and isotype control or anti-NGF neutral-
izing antibodies (75 μg/ml); (C) Matrigel was mixed with proNGF (7.5 μg/ml), NGF (3.75 μg/ml), or VEGF (0.375 μg/ml). Angiogenesis was analyzed by 
quantification of hemoglobin (A, C) and microvessel density (B) as described in materials and methods. Five mice were used for each group and results 
are the mean of three independent experiments. Student's t-test, *p < 0.01 versus control.
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Figure 2 Pleiotropic effects of NGF on HUVEC. (A) Growth assay. HUVEC cultured on standard culture plastic were treated with NGF (100 ng/ml), 
or VEGF (10 ng/ml) for 48 h. (B and C) Migration and invasion assay using Transwells. (D) Cord formation assay on matrigel-coated 24-well dishes. (E) 
Endothelial cell monolayer permeability assay. The kinetics of 70 kDa Dextran-FITC having passed through the monolayer of endothelial cells was de-
termined by measurement of fluorescence in the lower chambers at different time points. A to D Student's t-test, *p < 0.01 versus control. E, ANOVA 
test, p < 0.05.
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Figure 3 Involvement of TrkA, PI3K/Akt and MAPK pathways in NGF-stimulated invasion of HUVEC. (A) Western blot analysis of phospho TrkA 
(pTrkA), pAkt, and pERK upon NGF (100 ng/ml) stimulation. (B) Inhibition of pTrkA, pAkt and pERK by specific pharmacological inhibitors. HUVEC were 
pretreated with K252a, LY294002 or PD98059 for 30 min before treatment with NGF for another 20 min. For both A and B, results are representative 
of at least two independent experiments. (C) Invasion assay using Transwells. HUVEC were pretreated with the indicated pharmacological inhibitors 
for 30 min and then treated with NGF for 24 h. Student's t-test, *p < 0.01 versus control.
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Figure 4 Involvement of MMPs in NGF-stimulated invasion. (A) Invasion assay using Transwells. HUVEC were pretreated with the broad spectrum 
inhibitor of MMPs GM6001 (10 μM) or the specific inhibitor of MMP2 (MMP2 Inhibitor I, 5 μM) for 30 min and then treated with NGF (100 ng/ml) for 24 
h. Student's t-test, *p < 0.01 versus control. (B and C) Zymography analysis of MMP2. HUVEC were treated with NGF in the presence of different phar-
macological inhibitors as described above before zymography analysis. Results are representative of two independent experiments.
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Figure 5 Involvement of NO synthase in NGF-stimulated invasion. (A) Western blot analysis of phospho NO Synthase (pNOS) upon NGF (100 ng/
ml) treatment. Results were representative of two independent experiments. (B) Quantification of NO levels in HUVEC. Cells were pretreated with NO 
synthase inhibitor (L-NAME, 0.1 mM) for 30 min, then loaded with DAF-2DA for 20 min before treatment with NGF in the presence or absence of L-
NAME for 2 h. (C) Illustration of fluorescence intensity, which represent the levels of NO in HUVEC under different conditions. (D) Invasion assay using 
Transwells. HUVEC were pretreated with L-NAME and then treated with NGF for 24 h. For both B and D, Student's t-test, *p < 0.01 versus control.
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Figure 6 Involvement of the VEGF in NGF-stimulated angiogenesis. (A) ELISA quantification of VEGF in conditioned media from HUVEC and MDA-
MB-231 cells. Cells were treated with NGF (100 ng/ml) for 6 h or 24 h, conditioned media were concentrated before ELISA assay, as described in ma-
terials and methods. (B) Invasion assay using Transwells. HUVEC were treated with NGF (100 ng/ml) or VEGF (10 ng/ml) in the presence of isotype 
control or anti-VEGF neutralizing antibodies (1 μg/ml) for 24 h. (C) In vivo angiogenesis assay. Matrigel containing a mixture of NGF and isotype control 
or anti-VEGF neutralizing antibodies (37.5 μg/ml) was subcutaneously injected into SCID mice (five mice per group) as described in materials and 
methods. Hemoglobin in Matrigel plugs was quantified by Drabkin method 7 days after injection. Results are the mean of three independent exper-
iments. Student's t-test, *p < 0.01; #p < 0.05 versus control.
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lial cells [14], as well as epithelial ovarian cancer cells [32].
We decided to determine the potential implication of
VEGF in NGF-stimulated angiogenesis. As revealed by
ELISA assay (Fig. 6A), NGF strongly increased the levels
of secreted VEGF in both HUVEC and MDA-MB-231
breast cancer cells. Upon 24 h of treatment with NGF, an
increase of 63% and 43% of secreted VEGF was observed
in HUVEC and MDA-MB-231 cells, respectively. We
then determined the involvement of VEGF in NGF-stim-
ulated angiogenesis both in vitro and in vivo by using an
anti-VEGF neutralizing antibody. Although anti-VEGF
was able to totally abolish VEGF-induced invasion, neu-
tralization of VEGF led to 50% decrease of NGF-induced
invasion of HUVEC (Fig. 6B). Interestingly, similar result
was obtained when angiogenesis was determined using
Matrigel plugs in SCID mice (Fig. 6C). Collectively, these
results demonstrated that NGF-induced angiogenesis
was partially mediated by VEGF.
Discussion
Here, we present in vivo and in vitro data that give new
insights into mechanisms of the involvement of NGF in
breast cancer angiogenesis. Using an in vivo matrigel
model, we showed that strong angiogenesis was set up as
early as 7 days after subcutaneous injection of MDA-MB-
231 breast cancer cells in SCID mice. Importantly, neu-
tralization of NGF with antibody against NGF reduced
more than half of breast cancer cells-induced angiogene-
sis. These results reinforce our previous findings that
treatment of established xenografted mammary tumors
with a neutralizing antibody against NGF could reduce
the number of endothelial cells in the tumors [24]. More-
over, we found that the in vivo angiogenic effect of NGF
was similar to that elicited by VEGF; this is consistent
w i t h  d a t a  r e p o r t e d  b y  C a n t a r e l l a  e t  a l .  [ 1 4 ]  w h o  u s e d
chicken embryo chorioallantoic membrane (CAM) as an
in vivo angiogenesis assay. As VEGF is considered as one
of the most efficient proangiogenic factors in breast can-
cer angiogenesis [6,10], and as NGF is found to be overex-
pressed in breast cancer [24], our present findings
highlight the importance of NGF as a proangiogenic fac-
tor in breast cancer.
Tumor angiogenesis involves several processes, includ-
ing endothelial activation, proliferation, migration and
tissue infiltration from preexisting blood vessels that are
triggered by specific proangiogenic growth factors pro-
duced by tumor cells and the surrounding stroma [33].
These include VEGF [34] and bFGF [35] which have been
shown to activate their specific receptor tyrosine kinases,
thereby initiating intracellular signaling to drive the
angiogenic process. The effects of NGF on endothelial
cells have been found to vary according to tissue origin.
NGF stimulates proliferation and migration of human
umbilical vein endothelial cells, human dermal microvas-
cular endothelial cells and choroidal endothelial cells
[14,27,36,37]. In contrast, NGF has no effect on either
proliferation or migration of retinal endothelial cells [37].
Here, we showed that NGF strongly enhanced invasion
and cord formation of HUVEC with moderate effects on
proliferation and migration. Of importance, we showed
for the first time that NGF increased the permeability of
endothelial cell monolayer in vitro. The increased perme-
ability of intratumoral blood vessels is thought to favor
tumor cell extravasation during metastasis and to play a
crucial role in tumor stroma formation due to leak of
plasma fibrinogen [38,39].
As invasion of endothelial cells is one of the important
processes during angiogenesis, we decided to determine
the signaling pathways involved in NGF-stimulated inva-
sion of HUVEC. We demonstrated that NGF-stimulated
invasion was regulated via its tyrosine kinase receptor
TrkA; this was reinforced by the observation that
ProNGF, which acts via  other receptors (p75NTR  and
sortilin) than TrkA, had no effect on angiogenesis. More-
over, NGF-stimulated invasion was regulated by TrkA
downstream signaling pathways including PI3K and ERK,
leading to the activation of MMP2. These findings are
partially in agreement with data reported by Park et al
[27] in that they observed only the involvement of PI3K,
but not ERK, in NGF-induced HUVEC invasion and
MMP2 activation. The reason for such a discrepancy is
not known, as the same pharmacological inhibitor
(PD98059, 10 μM) was used in the two studies; one
hypothesis might be the difference of culture medium.
Alternatively, as HUVEC are derived from different
donors, we cannot exclude some differences due to their
origin, despite of the standardized protocol of cell isola-
tion and characterization.
Another interesting finding of our work was the
involvement of NO synthase (NOS) in NGF-induced
invasion. NOS is responsible for the production of nitric
oxide (NO), a highly diffusible signaling molecule, known
to mediate a number of functions such as angiogenesis,
immune responses and nervous system development
[40]. Endothelial NOS (eNOS), is particularly expressed
by vascular endothelial cells or surrounding stromal cells
and therefore has been a focus of attention in angiogene-
sis. Thus, using eNOS-/-mice, it has been found that NO
mediates branching and longitudinal extension of blood
vessels in B16 melanomas and that this process is pre-
dominantly mediated by eNOS [41]. In cell culture mod-
els, eNOS has been described to be involved in migration
of endothelial cells [30,31]. eNOS is also involved in the
proangiogenic effect of VEGF and prostaglandin E2
[42,43]. VEGF has been reported to stimulate endothelial
cell migration by activating Akt which in turn phosphory-Romon et al. Molecular Cancer 2010, 9:157
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lates Ser1177 residue of eNOS [30,44]. Here, we found
that NGF induced a rapid and persistent increase of
phosphorylation of NOS at Ser1177, accompanied by an
increase of NO production, suggesting that NGF-induced
phosphorylation of eNOS could also involve PI3K/Akt
pathway as previously described for VEGF [30,44].
NGF has been described to increase the expression of
VEGF in various tissues and cells such as ischemic
hindlimb [15,45], nervous system [46,47], epithelial ovar-
ian cancer cells [32] and endothelial cells [47]. Therefore,
NGF may exert its proangiogenic effect via  VEGF.
Indeed, we showed NGF can increase the secretion of
VEGF in both HUVEC and MDA-MB-231 breast cancer
cells. Moreover, NGF-promoted angiogenesis is partially
mediated by VEGF, as neutralizing antibody anti-VEGF
inhibited about half of NGF-induced HUVEC invasion,
as well as angiogenesis, in vivo. These data, together with
our previous findings of NGF overexpression in breast
cancer, suggest that NGF could favour breast cancer
angiogenesis in concert with VEGF.
Since anti-angiogenesis strategy using anti-VEGF anti-
bodies such as bevacizumab has been integrated into the
treatment of cancers, including breast cancer, the devel-
opment of bevacizumab-resistant tumors has become
more common. Recent studies show that targeting other
angiogenesis signaling pathways such as those induced by
angiopoietin/Tie-2 may lead to enhanced response in
anti-VEGF resistant tumors [48]. In this study, we pro-
vided direct evidence that NGF could be an important
stimulator for breast cancer angiogenesis. NGF not only
stimulates proliferation, migration, invasion and tubule
formation of endothelial cells, but also increases the per-
meability of endothelial cell monolayer. Furthermore, our
study allows for the identification of new pathways, such
as NO synthase and ERK, in NGF-induced invasion of
endothelial cells. Thus, NGF, as well as the activated sig-
naling pathways, should be taken into account for the
design of future anti-angiogenic therapeutic approaches
against breast cancer.
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